SeasonalAf f. Disorder

Transcription

1 SeasonalAf f [REVIEW] by KATHRYN A. ROECKLEIN and KELLY J. ROHAN, PhD Ms. Roecklein and Dr. Rohan are from the Department of Medical and Clinical Psychology, Uniformed Services University of the Health Sciences in Bethesda, Maryland. Disorder An Overview and Update 20 Psychiatry 2005 [JANUARY]

2 Seasonal affective disorder (SAD), characterized by fall/winter major depression ective with spring/summer remission, is a prevalent mental health problem. SAD etiology is not certain, but available models focus on neurotransmitters, hormones, circadian rhythm dysregulation, genetic polymorphisms, and psychological factors. Light therapy is established as the best available treatment for SAD. Alternative and/or supplementary approaches involving medications, cognitivebehavioral therapy, and exercise are currently being developed and evaluated. Given the complexity of the disorder, interdisciplinary research stands to make a significant contribution to ADDRESS FOR CORRESPONDENCE: Kelly J. Rohan, Department of Medical and Clinical Psychology, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD, ; Phone: (301) ; FAX: (301) ; krohan@usuhs.mil The opinions and assertions expressed herein are those of the authors and are not to be construed as expressing the views of the USUHS or the United States Department of Defense. advancing our understanding of SAD conceptualization and treatment. [JANUARY] Psychiatry

3 DESCRIPTION AND PREVALENCE Seasonal affective disorder (SAD) was first described as a syndrome involving depressive episodes that recur and remit annually in certain seasons. 1 The Diagnostic and Statistical Manual of Mental Disorders 2 includes a seasonal pattern specifier that can be applied to recurrent major depressive disorder or bipolar I or II disorder in cases where the major depressive episodes recur in a particular season and fully remit or change to mania or hypomania at a characteristic time of year. An estimated 10 to 20 percent of recurrent depression cases follow a seasonal pattern. 3 Although a summer pattern of recurrence is possible, the predominant pattern involves fall/winter depression with spring/summer remission. In U.S. community surveys, SAD prevalence ranges from 9.7 percent in New Hampshire to 1.4 percent in Florida. 4 In North America, SAD prevalence increases with latitude, but the correlation is nonsignificant in other parts of the world. 5 It is important to introduce the concept of seasonality and define it here. The construct of seasonality is relatively normally distributed in the general population, and the syndrome of SAD appears to represent an extreme along the seasonality continuum. 6 Young adults and women are most likely to experience SAD with the reported gender difference ranging from 2:1 to 9:1. 3 SAD also has been identified in children and adolescents. 7 Not limited to the mood disorders, seasonal patterns have been identified in bulimia nervosa, anxiety disorders, and other psychiatric conditions. 3 ETIOLOGICAL THEORIES Pathogenic theories for SAD have focused on neurotransmitters, hormones, circadian rhythm dysregulation, genetic polymorphisms, and psychological factors. In humans, the rate of serotonin turnover in the brain is lowest in the winter season, and the rate of serotonin production increases with luminosity. 8 Monoaminergic challenge and depletion studies implicate serotonergic systems in the pathogenesis of SAD. 9 Individuals with SAD successfully treated with bright light therapy relapse when serotonin and catecholamine levels are depleted. 10,11 Efficacy of the serotonin reuptake inhibitors (SSRIs) in SAD treatment provides indirect evidence for the role of serotonin in SAD. 12 Taken cumulatively, research suggests that serotonin and catecholamines may play a role in both the pathophysiology of SAD and the antidepressant effect of light therapy. The phase-shift hypothesis proposes that the body s sleep-wake cycle is phase-delayed in SAD with respect to the environmental lightdark cycle, 13 and is based on observations of delayed onset of sleep, melatonin, body temperature, and cortisol rhythms in some SAD patients. 14 Winter worsening of mood was associated with indirect measures of phase-delay in an Australian community sample. 15 Light therapy administered in the morning can phase-advance circadian rhythms in individuals with SAD who are phase-delayed. 16 The magnitude of the antidepressant response to morning light therapy has been related to the degree of phase-advance achieved. 17 However, it remains unclear how a phase-delay may lead to depression. The photon-count hypothesis suggests that shorter photoperiods (hours of daylight) and/or less intense light in the winter results in an insufficient dose of light (i.e., fewer photons) to the retina in SAD-vulnerable individuals. 18 A prospective, longitudinal study found a positive correlation between depression severity and photoperiod and two measures of light intensity (minutes of sunshine and global radiation) in SAD patients. 19 A recent light therapy meta-analysis found a doseresponse relationship between light therapy intensity and degree of improvement in the typical, but not in the atypical, depressive symptoms. 20 Individuals with SAD may respond to longer nights in winter with an extended duration of nocturnal melatonin release, a hormone that can promote sleep. 21 When measuring active melatonin secretion under constant dim light, Wehr, et al., 21 found that individuals with SAD had a longer duration of melatonin release during winter than summer whereas controls did not. This is analogous to the lengthened duration of melatonin release in some mammals that signals seasonal changes in reproductive activity. 21 It is possible that only humans with SAD have retained the ability to track seasons in this way, which might explain the seasonal presentation of SAD. Studies of twins, families with a SAD proband, and other relatively homogeneous groups indicate that SAD may be, in part, an inherited disorder. 22 Candidate genes related 22 Psychiatry 2005 [JANUARY]

4 to serotonin and dopamine and molecular components of the circadian clock have been investigated. Polymorphisms in the serotonin transporter promoter region (5-HTTLPR) and in the serotonin 2A receptor (5-HT2A-1483G/A) have been associated with SAD in some studies 23,24 but not others The dopamine-4 receptor gene (DRD4) seven-repeat allele was associated with binge eating behavior in a sample of women with SAD. 28 Neuronal PAS domain protein 2 (NPAS2), a transcription factor expressed in the circadian clock, was implicated in diurnal variation (preference for morning or evening) in a SAD case-control study. 29 These results suggest that SAD and specific SAD symptoms may be regulated by different genetic factors, each contributing a small-tomoderate amount of risk. 30 Recent etiological models have attempted to integrate biological and psychological mechanisms in explaining SAD onset and maintenance. Young s dual vulnerability model proposes two separate vulnerabilities among individuals with history of SAD: 1) a physiological vulnerability to experience atypical symptoms during the winter and 2) a psychological vulnerability to develop cognitive and affective symptoms of depression in reaction to the vegetative symptoms. 31 Young devised this hypothesis based on his finding that individuals with SAD retrospectively recounted onset of fatigue, hypersomnia, and increased appetite prior to developing cognitive and affective symptoms. 32 Different pathophysiological mechanisms may account for the different vulnerabilities proposed, leading to heterogeneity of findings from studies addressing the etiology and treatment of SAD. 33 Evidence is growing that cognitive and behavioral models of depression may apply to SAD. In Pathogenic theories for SAD have focused on neurotransmitters, hormones, circadian rhythm dysregulation, genetic polymorphisms, and psychological factors. two cross-sectional studies, individuals with SAD and nonseasonal depression reported similarly negative attributional styles 34 and similar negative automatic thoughts and dysfunctional attitudes. 35 A prospective, longitudinal study found that women with a SAD history endorsed more frequent negative automatic thoughts than nondepressed controls across all seasons, with peak negative automatic thought frequency in the winter. 36 Two studies found that ruminative coping (i.e., focusing on the causes and consequences of depressed mood,) as assessed in the fall, predicted the severity of SAD symptoms during the subsequent winter. 36,37 Behavioral disengagement is underscored by the progression of decline in SAD from reduced potential for enjoyment in fall to decreased frequency of response-contingent positive reinforcement in the winter. 36 TREATMENT APPROACHES The most widely used and extensively investigated treatment for SAD is light therapy (i.e., daily exposure to a box containing fluorescent lamps during the symptomatic months). Certain activities, such as reading, are not prohibited as long as the user can maintain the appropriate position and distance from the unit. Regarding the optimal dose, 10,000-lux of full spectrum or cool white fluorescent lights set behind an ultraviolet shield is the standard. 38 The recommended daily duration varies from 30 minutes to two hours per day, and two to four weeks is typically adequate to determine responsiveness. 38 The greatest controversy surrounds the optimal timing of light therapy. Head-to-head comparisons suggest that morning light may be more efficacious than evening light, [JANUARY] Psychiatry

5 but one meta-analysis found the largest mean effect size for morning-plus-evening light. 39 A growing variety of portable, head-mounted light visors, smaller desk lamp units, dawn stimulators, and light fixtures with light-emitting diodes (LEDs) have also been developed. More research is needed to determine whether these devices are as effective as standard light boxes for SAD. Available guidelines recommend administering light therapy under the supervision of a qualified professional. 38 In clinical settings, the specific light therapy prescription is often tailored to the individual s sleepwake patterns, side effects, and preferences. Side effects to light therapy are generally mild and ameliorated by dose manipulations, but can include headache, eyestrain, and psychomotor agitation. Relative contraindications for light therapy include certain retinal diseases, medications that increase retinal sensitivity to light, and a history of mania or hypomania. A pooled analysis of light therapy studies 40 concluded that 53.3 percent of individuals with SAD met criteria for full remission with light therapy. However, only 43 percent of individuals with moderate to severe SAD symptoms remitted with light therapy. 41 Supplementary and alternative treatments have been developed because light therapy is not sufficient for all SAD patients. Clinically, the SSRIs and other psychotropic medications are frequently used as an adjunct or alternative to light therapy. 42,43 A preliminary study found that light therapy plus pill placebo (50%) had a higher remission rate than fluoxetine plus dim light placebo (25%). 44 Most recently, a five-center Canadian study found comparable remission rates for light therapy The established efficacy of light therapy and a variety of newly emerging treatment approaches to SAD affords providers with flexible options that can be tailored to individuals... plus pill placebo (54%) and fluoxetine plus dim light placebo (50%). 45 In a retrospective analysis of SAD outpatients in Finland, 73 percent of eight patients treated with moclebemide and 61 percent of 11 patients treated with fluoxetine responded over six weeks. 46 A study that randomized eight women with SAD to combined light therapy and citalopram or light therapy and pill placebo found no difference in the two conditions at post-treatment, but greater efficacy for combination treatment 34 weeks later. 47 A randomized trial comparing sertraline to pill placebo for eight weeks demonstrated greater improvements with setraline on measures of depression severity. 48 In addition to antidepressants, other pharmacologic agents show promise in treating SAD. One openlabel study found that modafinil, a novel wake-promoting agent, demonstrated a 67-percent response rate, defined as a 50- percent or greater reduction in SAD symptoms, indicating that randomized, controlled studies may be warranted. 49 Propranolol, administered in the morning in open treatment for two weeks, produced a 73-percent response rate in a sample of 33 SAD patients, although not all treatment gains were maintained over the subsequent two weeks in the active drug continuation group versus placebo. 50 Future studies should examine propranolol s melatonin-suppressing effects as a mediator of antidepressant response in SAD. 50 Our group has recently developed and pilot-tested a SAD-tailored version of cognitive-behavioral therapy (CBT), modeled upon Beck s cognitive therapy, 51 which is an empirically validated treatment for non-seasonal depression. The CBT for SAD protocol involves 90- minute sessions twice a week over 24 Psychiatry 2005 [JANUARY] 24

6 six weeks (total of 12 sessions) delivered in group format. The behavioral component uses pleasant activity scheduling to counteract hibernation by developing wintertime interests. Negative cognitions are identified and challenged, including thoughts related to winter, light availability, seasonal environmental cues, and weather. Relapse-prevention emphasizes using CBT skills during subsequent fall/winter seasons in response to anticipatory negative thoughts about winter or SAD-related behavior changes. Our feasibility study found that CBT, light therapy, and their combination were equally effective in the acute treatment of SAD. 52 At a naturalistic one-year follow up, individuals treated with CBT, with or without adjunct light therapy, evidenced less severe depression on patient- and interviewer-rated measures. No CBT-treated participant met criteria for a full SAD episode recurrence relative to 62.5 percent of participants treated with light therapy alone. We have completed a larger sample, multiyear trial comparing CBT, light therapy, and combination therapy to a waitlist control with manuscript preparation underway. Aerobic exercise interventions, which have demonstrated efficacy in the treatment of nonseasonal major depression, 53,54 are being explored in SAD. Pinchasov, et al., compared light therapy to aerobic exercise (i.e., two daily sessions on a stationary bicycle separated by five minutes of rest, each involving a 5-minute warm up followed by 10 minutes of basic pedaling and 10 minutes of pedaling at 75-percent maximal heart rate), with both treatments administered for one week during the afternoon, in a small sample of women with SAD. 55 Exercise and light therapy were associated with similar and significant reductions in depression severity and an increased rate of oxygen consumption relative to an untreated control group, suggesting that normalization of daily energy expenditure may underlie the efficacy of both treatments. Although morning exercise might be beneficial in the treatment of SAD, based on the assumption that it would induce a phaseadvance, these results suggest that the timing of exercise may not be important to the antidepressant effects of exercise on SAD. However, exercise late at night might be contraindicated in SAD because it can lead to a phasedelay in the onset of melatonin release the following night in humans. 56 In healthy controls, aerobic exercise performed under bright (2,500- to 4,000-lux) lights appears to be more beneficial than either exercise under typical indoor lighting or no exercise for atypical symptoms and vitality. 57 Therefore, outdoor exercise or combining aerobic exercise with light therapy might have utility for SAD, but has not yet been tested. Larger controlled trials are needed to further test exercise as an alternative or adjunctive treatment strategy in SAD. CONCLUSIONS Given its predictable pattern of recurrence and remission, SAD provides a natural laboratory for studying depression vulnerability, onset, maintenance, recurrence, and treatment response. SAD is likely to result from a complex interplay between environmental, biological, and psychological factors. Therefore, interdisciplinary research is needed to advance scientific knowledge regarding SAD etiology, treatment, and reasons behind the widely documented increased incidence of SAD among women. The established efficacy of light therapy and a variety of newly emerging treatment approaches to SAD affords providers with flexible options that can be tailored to individuals, keeping in mind patient compliance and perceived palatability of the treatment plan as important considerations. REFERENCES 1. Rosenthal NE, Sack DA, Gillin JC, et al. Seasonal affective disorder. A description of the syndrome and preliminary findings with light therapy. Arch Gen Psychiatry 1984;41: American Psychiatric Association. The Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR, Fourth Edition. Washington, DC: American Psychiatric Association, Magnusson A. An overview of epidemiological studies on seasonal affective disorder. Acta Psychiatr Scand 2000;101: Rosen L, Targum S, Terman M, et al. Prevalence of seasonal affective disorder at four latitudes. Psychiatry Res 1990;31: Mersch P, Middendorp H, Bouhuys A, et al. Seasonal affective disorder and latitude: A review of the literature. J Affect Disord 1999;53: Kasper S, Wehr TA, Bartko JJ, et al. Epidemiological findings of seasonal changes in mood and behavior. A telephone survey of Montgomery County, Maryland. Arch Gen Psychiatry 1989;46: Swedo SE, Pleeter JD, Richter DM, et al. Rates of seasonal affective disorder in children and adolescents. Am J Psychiatry 1995;152: Lambert G, Reid C, Kaye D, et al. Effect of sunlight and season on serotonin turnover in the brain. Lancet 2002;360: Maes M, Neumeister A, Konstantinidis A, et al. Monoaminergic function in the pathogenesis of seasonal affective disorder. Int J Neuropsychopharmacol 2001;4: [JANUARY] Psychiatry

7 10. Lam RW, Zis AP, Grewal A, et al. Effects of rapid tryptophan depletion in patients with seasonal affective disorder in remission after light therapy. Arch Gen Psychiatry 1996;53: Neumeister A, Turner EH, Matthews JR, et al. Effects of tryptophan depletion vs catecholamine depletion in patients with seasonal affective disorder in remission with light therapy. Arch Gen Psychiatry 1998;55(6): Lam R, Gorman C, Michalon M, et al. Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder. Am J Psychiatry 1995;152: Lewy AJ, Sack RL, Singer CM, White DM. The phase shift hypothesis for bright light s therapeutic mechanism of action: theoretical considerations and experimental evidence. Psychopharmacol Bull 1987;23: Magnusson A, Boivin D. Seasonal affective disorder: An overview. Chronobiol Int 2003;20: Murray G, Allen NB, Trinder J. Seasonality and circadian phase delay: Prospective evidence that winter lowering of mood is associated with a shift towards eveningness. J Affect Disord 2003;76: Lewy AJ, Bauer VK, Cutler NL, et al. Morning vs evening light treatment of patients with winter depression. Arch Gen Psychiatry 1998;55: Terman JS, Terman M, Lo ES, Cooper TB. Circadian time of morning light administration and therapeutic response in winter depression. Arch Gen Psychiatry 2001;58: Rosenthal NE, Moul DE, Hellekson CJ, et al. A multicenter study of the light visor for seasonal affective disorder: no difference in efficacy found between two different intensities. Neuropsychopharmacology 1993;8: Molin J, Mellerup E, Bolwig T, et al. The influence of climate on development of winter depression. J Affect Disord 1996;37: Lee TMC, Chan CCH. Dose-response relationship of phototherapy for seasonal affective disorder: A meta-analysis. Acta Psychiatr Scand 1999;99: Wehr TA, Duncan WC, Jr., Sher L, et al. A circadian signal of change of season in patients with seasonal affective disorder. Arch Psychiatr Scand 1999;99(5): Sher L, Goldman D, Ozaki N, Rosenthal NE. The role of genetic factors in the etiology of seasonal affective disorder and seasonality. J Affect Disord 1999;53: Enoch MA, Goldman D, Barnett R, et al. Association between seasonal affective disorder and the 5-HT2A promoter polymorphism, -1438G/A. Mol Psychiatry 1999;4: Rosenthal N, Mazzanti C, Barnett R, et al. Role of serotonin transporter promoter repeat length polymorphism (5-HTTLPR) in seasonality and seasonal affective disorder. Mol Psychiatry 1998;3: Johansson C, Willeit M, Levitan R, et al. The serotonin transporter promoter repeat length polymorphism, seasonal affective disorder and seasonality. Psychol Med 2003;33: Johansson C, Smedh C, Partonen T, et al. Seasonal affective disorder and serotoninrelated polymorphisms. Neurobiol Dis 2001;8: Lenzinger E, Neumeister A, Praschak- Rieder N, et al. Behavioral effects of tryptophan depletion in seasonal affective disorder associated with the serotonin transporter gene? Psychiatry Res 1999;85: Levitan RD, Masellis M, Basile VS, et al. The dopamine-4 receptor gene associated with binge eating and weight gain in women with seasonal affective disorder: An evolutionary perspective. Biol Psychiatry 2004;56: Johansson C, Willeit M, Smedh C, et al. Circadian clock-related polymorphisms in seasonal affective disorder and their relevance to diurnal preference. Neuropsychopharmacology 2003;28: Sher L. Genetic studies of seasonal affective disorder and seasonality. Compr Psychiatry 2001;42: Young MA. Integrating psychological and physiological mechanisms of SAD: The dual-vlunerability model. Biological Rhythms Bulletin 1999;1: Young MA, Watel LG, Lahmeyer HW, Eastman CI. The temporal onset of individual symptoms in winter depression: Differentiating underlying mechanisms. J Affect Disord 1991;22: Lam RW, Tam EM, Yatham LN, et al. Seasonal depression: The dual vulnerability hypothesis revisited. J Affect Disord 2001;63: Levitan RD, Rector NA, Bagby RM. Negative attributional style in seasonal and nonseasonal depression. Am J Psychiatry 1998;155: Hodges S, Marks M. Cognitive characteristics of seasonal affective disorder: A preliminary investigation. J Affect Disord 1998;50: Rohan KJ, Sigmon ST, Dorhofer DM. Cognitive-behavioral factors in seasonal affective disorder. J Consult Clin Psychol 2003;71: Young MA, Azam OA. Ruminative response style and the severity of seasonal affective disorder. Cognit Ther Res ;27: Lam RW, Levitt AJ (eds). Canadian Consensus Guidelines for the Treatment of Seasonal Affective Disorder. Vancouver, BC: Clinical and Academic Publishing, Lee TMC, Chan CCH, Paterson JG, et al. Spectral properties of phototherapy for seasonal affective disorder: A meta-analysis. Acta Psychiatr Scand 1997;96: Terman MA, Terman JS, Quitkin FM, et al. Light therapy for seasonal affective disorder. A review of efficacy. Neuropsychopharmacology 1989;2: Terman M, Amira L, Terman JS, Ross DC. Predictors of response and nonresponse to light treatment for winter depression. Am J Psychiatry 1996;153: Schwartz PJ, Brown C, Wehr TA, Rosenthal NE. Winter seasonal affective disorder: A follow-up study of the first 59 patients of the National Institute of Mental Health Seasonal Studies Program. Am J Psychiatry 1996;153: Pjrek E, Winkler D, Stastny J, et al. Bright light therapy in seasonal affective disorder: Does it suffice? Eur Neuropsychopharmacol 2004;14: Ruhrmann S, Kasper S, Hawellek B, et al. Effects of fluoxetine versus bright light in the treatment of seasonal affective disorder. Psychol Med 1998;28: Lam RW, Levitt AJ, Levitan R, et al. The CAN-SAD study: A Canadian multicentre study of light versus fluoxetine treatment in patients with seasonal affective disorder. Paper presented at Society for Light Therapy and Biological Rhythms, 2004; Toronto, Ontario. 46. Partonen T, Lonnqvist J. Moclobemide and fluoxetine in treatment of seasonal affective disorder. J Affect Disord 1996;41: Thorell LH, Kjellman B, Arned M, et al. Light treatment of seasonal affective disorder in combination with citalopram or placebo with 1-year follow-up. Int Clin Psychopharmacol 1999;14(Suppl 2):S Moscovitch A, Blashko CA, Eagles JM, et al. A placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder. Psychopharmacology (Berl) 2004;171: Lundt L. Modafinil treatment in patients with seasonal affective disorder/winter depression: An open-label pilot study. J Affect Disord 2004;81: Schlager DS. Early-morning administration of short-acting beta blockers for treatment of winter depression. Am J Psychiatry 1994;151: Beck AT, Rush AJ, Shaw BF, Emery G. Cognitive Therapy of Depression. New York, NY: Guilford Press, Rohan KJ, Tierney Lindsey K, et al. Cognitive-behavioral therapy, light therapy, and their combination in treating seasonal affective disorder. J Affect Disord 2004;80: Blumenthal JA, Babyak MA, Moore KA, et al. Effects of exercise training on older patients with major depression. Arch Intern Med 1999;159: Babyak M, Blumenthal JA, Herman S, et al. Exercise treatment for major depression: Maintenance of therapeutic benefit at 10 months. Psychosom Med 2000;62: Pinchasov BB, Shurgaja AM, Grischin OV, Putilov AA. Mood and energy regulation in seasonal and non-seasonal depression before and after midday treatment with physical exercise or bright light. Psychiatry Res 2000;94: Buxton OM, L Hermite-Baleriaux M, Hirschfeld U, Cauter E. Acute and delayed effects of exercise on human melatonin secretion. J Biol Rhythms 1997;12: Partonen T, Leppamaki S, Hurme J, Lonnqvist J. Randomized trial of physical exercise alone or combined with bright light on mood and health-related quality of life. Psychol Med 1998;28: Psychiatry 2005 [JANUARY]